Insurance telemarketing CEO sentenced to 25 years in federal prison for lying to consumers

The owner of a health insurance telemarketing company was sentenced to 25 years in federal prison for selling limited indemnity health insurance plans using false and deceptive practices. The Federal Trade Commission also had the courts liquidate the company’s assets earlier this year. 

Steven Dorfman, 40, of Fort Lauderdale, Florida, owned, operated, and functioned as the CEO of Simple Health. In February, a jury convicted Dorfman of one count of conspiracy to commit mail and wire fraud, four counts of mail fraud and eight counts of wire fraud in connection with his operation of Simple Health and its sales of limited indemnity health insurance plans. He was sentenced July 25 by a district court judge in southern Illinois to 25 years in prison, followed by five years of supervised release.

“Steven Dorfman orchestrated a scam to enrich himself by deceiving thousands of victims. He directed sales agents at his telemarketing company to lie to consumers and trick them into believing the limited indemnity insurance plans they were peddling would function like major medical insurance,” said U.S. Attorney Rachelle Aud Crowe in a statement. “This brazen fraud had lasting, and financially disastrous, effects on many victims." 

Simple Health salespersons had promised that the policies would cover most medical expenses. Aud Crowe said that, when the victims attempted to use these policies, they found out they had little to no coverage. As a result, victims were left owing thousands of dollars for medical services that were not covered by the limited indemnity plans sold by Simple Health.

According to court documents and evidence presented during the trial, Dorfman’s company trained employees to use deceptive sales tactics to scam consumers into purchasing the limited indemnity insurance plans. These plans cover relatively low amounts of medical expenses. Once the low caps were reached, the consumers were then responsible for paying 100% of their medical expenses.

Aud Crowe’s office said the company used deceptive scripts and the blatant lies to mislead consumers and sell these low-value health insurance policies to more than 400,000 unsuspecting victims across the country between May 2012 and November 2018. The company generated more than $190 million in revenue, selling more than 1,400 of these limited indemnity policies to individuals from all 38 counties in the Southern District of Illinois.

Court documents said following these scripts Dorfman provided, salespeople would make statements such as “the whole idea of this plan is to make your out-of-pocket expenses as low as possible” and “when all is said and done, you’ll end up owing pennies on the dollar.” Evidence at trial also established that Simple Health’s commissioned salespersons frequently told additional, off-script lies to the consumers to get them to buy them to buy the policies, with little to no effort by Dorfman to stop this practice.

“This sentencing is a statement that mail fraud will not be tolerated, and the perpetrators will be brought to justice,” Acting Inspector in Charge, John Jackman, who leads the St. Louis Field Office of the U.S. Postal Inspection Service said in a statement. “The Postal Inspection Service will continue to partner with other law enforcement agencies to collectively pursue criminals who victimize postal customers and U.S. consumers.”

Two co-conspirators were also charged in the conspiracy, according the the U.S. attorney's office. Simple Health Chief Compliance Officer Candida Girouard, 47, of Valrico, Florida, pleaded guilty to the conspiracy charge in November 2023 and was sentenced in May to six months in prison.

Simple Health’s vice president of sales John A. Sand, 50, of Fort Lauderdale, Florida, was tried at the same time as Dorfman and was convicted by the jury on all counts contained in the indictment. But at a post-trial hearing a federal judge assigned to the case granted Sand’s motion for judgment of acquittal notwithstanding the verdict. The government is currently considering whether to appeal that decision.

FTC involvement in shutting down Simple Health fraud 

The investigation began with a referral from the Federal Trade Commission (FTC) Midwest Regional Office in Chicago. The FTC filed a complaint for civil injunctive relief in October 2018. The FTC’s action ended the fraud and a court-appointed receiver was appointed to take over Simple Health’s business operations. 

Read more about the 2018 action: FTC accuses Florida agency of selling $100M in fraudulent insurance plans.

In February 2024, the FTC obtained a $195 million judgment against Simple Health Plans LLC and Dorfman over charges they duped consumers into signing up for sham healthcare plans that did not deliver the coverage or benefits they promised. The court ordered that all of Simple Health's assets, which have been frozen since November 2018, be liquidated and all the proceeds be turned over to the FTC to provide refunds to consumers. 

When Simple health closed down in April 2024, records for patients were transferred to telemedicine company Twentyeight Health so they could continue receiving telemedicine care and prescriptions.

In addition to the banned conduct, the order also prohibits any misrepresentations in the sale of any good or service. The defendants also are prohibited from collecting any money for any healthcare product they previously sold and are required to destroy any personal information they collected about their customers.

Link to the summary judgement.

“Simple Health preyed on consumers by selling them bogus healthcare insurance that cost them thousands of dollars for ‘benefits’ that in fact left consumers unprotected,” Samuel Levine, director of the FTC’s Bureau of Consumer Protection, said in a statement. “We are pleased the court recognized this blatant bait and switch and ordered the company and its CEO to turn over the money they bilked from consumers.”

Dave Fornell is a digital editor with Cardiovascular Business and Radiology Business magazines. He has been covering healthcare for more than 16 years.

Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.